|Drug Patent Number||Company||Drug Patent Title||Drug Patent Expiry||Activity Alert|
|These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.|
|US9283209||NOVARTIS PHARMS CORP||Oral formulations of deferasirox|| |
(11 years from now)
Jadenu is owned by Novartis Pharms Corp.
Jadenu contains Deferasirox.
Jadenu has a total of 1 drug patent out of which 0 drug patents have expired.
Jadenu was authorised for market use on 30 March, 2015.
Jadenu is available in tablet;oral dosage forms.
The generics of Jadenu are possible to be released after 21 November, 2034.
|Drug Exclusivity||Drug Exclusivity Expiration|
|M (M)||Jul 23, 2023|
Market Authorisation Date: 30 March, 2015
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic